comparemela.com
Home
Live Updates
First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China : comparemela.com
First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related Keywords
China
,
Beijing
,
Taiwan
,
Japan
,
United States
,
Massachusetts
,
America
,
James Xue
,
Chris Brinzey
,
Drug Administration
,
Planet Communications
,
Children Hospital Of Capital Institute Pediatrics
,
University Of Washington School Medicine
,
Canbridge Pharmaceuticals Inc
,
Mirum Pharmaceuticals Inc
,
Canbridge Pharmaceuticals
,
Umass Chan Medical School
,
Capital Institute
,
Mirum Pharmaceuticals
,
Pilot Implementation Policy
,
Mirum Pharmaceuticals Sponsored
,
North America
,
Breakthrough Therapy
,
Wuxi Biologics
,
Chan Medical School
,
Washington School
,
Scriptr Global
,
Pharmaceuticals Inc
,
Investor Relations
,
Business Wire
,
Technology
,
Health
,
Clinical Trials
,
Business
,
comparemela.com © 2020. All Rights Reserved.